Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04968314 · ClinicalTrials.gov registry record
ChiPP2: A Trauma-Informed Program for City School Parents
A clinical trial, sponsored by Johns Hopkins University.
- Completed
- Registry status
- 244
- Enrollment target
NCT04968314: Completed study, sponsored by Johns Hopkins University.
NCT04968314 is a clinical trial that has completed, run by Johns Hopkins University. The registered enrollment target is 244 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04968314 has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- 244 participants
- Enrollment target
Study Summary
Purpose of this study is to assess the prevalence of adverse childhood experiences (ACEs) and positive childhood experiences (PCEs) among parents enrolled in the Chicago Parent Program (ChiPP) in their child's school and whether those experiences are associated with a) parents' participation in ChiPP and b) program benefits for parents and children.
Primary Outcome
Number of Chicago Parent Program group sessions attended (range from 0-12 sessions)
Interventions
- BEHAVIORAL Chicago Parent Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2020-02-28 |
| Est. Completion | 2024-06-17 |
What the finished NCT04968314 record still lists
NCT04968314 is an observational study that tracks outcomes without assigning an intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Chicago Parent Program is the first listed.
NCT04968314 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04968314 about?
NCT04968314 is a clinical study titled "ChiPP2: A Trauma-Informed Program for City School Parents". Purpose of this study is to assess the prevalence of adverse childhood experiences (ACEs) and positive childhood experiences (PCEs) among parents enrolled in the Chicago Parent Program (ChiPP) in their child's school and whether those experiences are associated with a) parents' participation in ChiP...
What is the current status of trial NCT04968314?
This trial is currently completed. The enrollment target is 244 participants. The study started on 2020-02-28. Estimated completion is 2024-06-17.
What interventions are being tested in trial NCT04968314?
The interventions under investigation include: Chicago Parent Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT04968314?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI